One common mutation in cancers is the substitution of His1047 of the kinase domain of p110a by arginine. The structure of the H1047R mutant of the p110a/p85a complex was determined alone and complex with wortmanin, a promiscuous kinase inhibitor . The structures show that this mutation dramatically changes the conformation of the C-terminal loop. In the wild-type structure, amino acids past residue 1047 are not ordered. In the mutant,however, the same residues are folded in such a way that part of this loop is now able to interact with the membrane. Increased interaction with the membrane provides the mutant enzyme greater accessibility to the PIP2 substrate and therefore higher enzymatic activity. If this is the mechanism of activation by this mutation, it can be expected that the activity of the H1047R mutant can
be further increased by binding pY-pep. have shown that this is indeed the case, further
supporting this mechanism.
One common mutation in cancers is the substitution of His1047 of the kinase domain of p110a by arginine. The structure of the H1047R mutant of the p110a/p85a complex was determined alone and complex with wortmanin, a promiscuous kinase inhibitor . The structures show that this mutation dramatically changes the conformation of the C-terminal loop. In the wild-type structure, amino acids past residue 1047 are not ordered. In the mutant,however, the same residues are folded in such a way that part of this loop is now able to interact with the membrane. Increased interaction with the membrane provides the mutant enzyme greater accessibility to the PIP2 substrate and therefore higher enzymatic activity. If this is the mechanism of activation by this mutation, it can be expected that the activity of the H1047R mutant can be further increased by binding pY-pep. have shown that this is indeed the case, furthersupporting this mechanism.
การแปล กรุณารอสักครู่..